Evidence map›Paper›PMID 41410866›Full record

ReviewCancer immunology, immunotherapy : CII2025

Immune biomarkers for head and neck cancer.

Navid Sobhani, Alberto D'Angelo, Fernanda G Kugeratski, Tristan Nguyen, Rachel M Morris, Raheleh Roudi, Nikta Kia, Luca Pianta, Riccardo Morello, Stuart Winter and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Navid SobhaniDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. NSobhani@mdanderson.org.
Alberto D'AngeloDepartment of Medicine, Sheffield Teaching Hospital NHS, Foundation Trust, Sheffield, S57AT, UK.
Fernanda G KugeratskiDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Tristan NguyenDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Rachel M MorrisDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Raheleh RoudiDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, CA, 94305, USA.
Nikta KiaAcute and Critical Care Division, College of Nursing, University of Iowa, Lowa City, IA, USA.
Luca PiantaENT Unit, ASST of Cremona, 26100, Cremona, Italy.
Riccardo MorelloENT Unit, ASST of Cremona, 26100, Cremona, Italy.
Stuart WinterNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Daniele GeneraliDepartment of Medicine, Surgery and Health Sciences, University of Trieste, 34100, Trieste, Italy.
Alexandro MembrinoDepartment of Medicine (DMED), University of Udine, 33100, Udine, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, head and neck cancer therapy has been revolutionized by immunotherapy, which aims to restore the immune system's anticancer activity suppressed by cancer cells. The major concern is that only a subset of patients responds to this therapy. Having specific biomarkers that could help identify the patients who are most likely to benefit from immunotherapies would be extremely useful. This review first explains the current immunotherapies tested in head and neck cancer, to then delve into the current prognostic and predictive biomarkers that have been investigated in this field to predict their responses. In our opinion, a broader selection of biomarkers could further improve who will respond best to immunotherapy.

Indexed as

Biomarkers, TumorHead and Neck NeoplasmsImmunotherapyHumansPrognosisBiomarkers, TumorHead and neck cancerImmune biomarkersImmunotherapyStratification

Identifiers

PMID41410866
PMCPMC12715102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.